A carregar...
Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting
Sclerostin antibody (romosozumab) was recently approved for clinical use in the United States to treat osteoporosis. We and others have explored Wnt‐based combination therapy to disproportionately improve the anabolic effects of sclerostin inhibition, including cotreatment with sclerostin antibody (...
Na minha lista:
| Publicado no: | JBMR Plus |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8101614/ https://ncbi.nlm.nih.gov/pubmed/33977198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10462 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|